替罗非班对急性非ST段抬高心肌梗死患者血清心肌肌钙蛋白T水平及近期预后的影响  

Effects of tirofiban on serum cardiac troponin T and prognosis in patients with acute non-ST-segment elevation myocardial infarction

作　　者：温汝军 周靖雯 罗育鑫 李耀庭 梁啦迪 曹健锋 

机构地区：[1]深圳市龙华区人民医院药剂科,广东深圳518109 [2]深圳市龙华区人民医院护理部,广东深圳518109 [3]深圳市龙华区人民医院心内科,广东深圳518109

出　　处：《海南医学》2017年第23期3805-3807,共3页Hainan Medical Journal

摘　　要：目的探讨替罗非班对急性非ST段抬高心肌梗死(NSTEMI)患者血清心肌肌钙蛋白T(c TNT)水平及近期预后的影响。方法选择2016年1月至2017年1月期间深圳市龙华区人民医院心内科收治的68例NSTEMI患者为研究对象,根据随机数表法将患者分为观察组和对照组,每组34例,对照组给予阿司匹林联合氯吡格雷抗血小板治疗,观察组在此基础上联合应用替罗非班治疗,疗程均为7 d。比较两组患者治疗后c TNT的动态变化及并发症发生情况、主要心脏不良事件(MACE)发生率。结果观察组患者c TNT水平在治疗后12 h、24 h时分别为(1.74±0.69)?g/L、(1.45±0.47)?g/L,均明显低于对照组的(2.46±0.95)?g/L、(1.92±0.64)?g/L,差异均有统计学意义(P<0.05);观察组与对照组患者出血发生率分别为14.71%和8.82%,差异无统计学意义(P>0.05);随访30 d,观察组患者MACE发生率8.82%,明显低于对照组的23.53%,差异有统计学意义(P<0.05)。结论替罗非班治疗NSTEMI可以有效减轻心肌损伤、改善近期预后,并且不增加出血等并发症的发生率。Objective To investigate the effect of tirofiban on serum cardiac troponin T（c TNT） level and short-term prognosis in patients with acute non-ST-segment elevation myocardial infarction（NSTEMI）. Methods During Janu-ary 2016 to January 2017, 68 NSTEMI patients treated in Department of Cardiology in Shenzhen Longhua People＇s Hospi-tal were selected as research objects. According to the random number table, the patients were divided into observationgroup（n=34） and control group（n=34）. The control group was treated by aspirin and clopidogrel antiplatelet therapy, andthe observation group applied tirofiban based on the treatment of the control group, both for 7 days. The two groups werecompared in dynamic changes of c TNT and complications, major adverse cardiac events（MACE） occurrence rate. Results In the observation group, c TNT levels after treatment at 12 h and 24 h respectively were（1.74±0.69） μg/L,（1.45±0.47） μg/L, significantly lower than（2.46±0.95） μg/L,（1.92±0.64） μg/L in the control group（P〈0.05）; bleeding rate was14.71% in the observation group and 8.82% in the control group（P〈0.05）; after follow-up of 30 days, the MACE rate inthe observation group was 8.82%, significantly lower than 23.53% in the control group（P〈0.05）. Conclusion Tirofibanin the treatment of NSTEMI can effectively reduce myocardial injury, improve short-term prognosis, and does not increasethe incidence of bleeding and other complications.

关 键 词：替罗非班 急性非ST段抬高心肌梗死 心肌肌钙蛋白T 预后 

分 类 号：R542.22[医药卫生—心血管疾病]